Retraction: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
Main Author: | Frontiers Editorial Office |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-06-01
|
Series: | Frontiers in Medicine |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.964099/full |
Similar Items
-
Expression of Concern: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
by: Frontiers Editorial Office
Published: (2022-01-01) -
RETRACTED: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
by: John McCoy, et al.
Published: (2021-07-01) -
Expression of Concern: The Effects of Vitamin D Supplementation on Signaling Pathway of Inflammation and Oxidative Stress in Diabetic Hemodialysis: A Randomized, Double-Blind, Placebo-Controlled Trial
by: Frontiers Editorial Office
Published: (2020-09-01) -
Erratum: Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial
by: Frontiers Production Office
Published: (2023-09-01) -
Randomized, Double-Blind, Placebo-Controlled Trial of a Throat Spray with Selected Lactobacilli in COVID-19 Outpatients
by: Ilke De Boeck, et al.
Published: (2022-10-01)